{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:15:22Z","timestamp":1788304522788,"version":"build-2803163510"},"publisher-location":"New York, NY","reference-count":34,"publisher":"Springer US","isbn-type":[{"value":"9781071652718","type":"print"},{"value":"9781071652725","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5272-5_5","type":"book-chapter","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:34:34Z","timestamp":1788302074000},"page":"81-96","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Detection of Unlabeled Oligonucleotides in FFPE Tissue Sections Using Automated miRNAscope Assays"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9533-5839","authenticated-orcid":false,"given":"Bradley","family":"Spencer-Dene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,2]]},"reference":[{"key":"5_CR1","unstructured":"Nonclinical safety assessment of oligonucleotide-based therapeutics. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/nonclinical-safety-assessment-oligonucleotide-based-therapeutics. https:\/\/www.fda.gov\/media\/183496\/download"},{"issue":"6","key":"5_CR2","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1124\/dmd.121.000417","volume":"50","author":"JM Migliorati","year":"2022","unstructured":"Migliorati JM, Liu S, Liu A et al (2022) Absorption, distribution, metabolism, and excretion of US Food and Drug Administration-approved antisense oligonucleotide drugs. Drug Metab Dispos 50(6):888\u2013897","journal-title":"Drug Metab Dispos"},{"key":"5_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1006304","volume":"13","author":"S Thakur","year":"2022","unstructured":"Thakur S, Sinhari A, Jain P, et al (2022) A perspective on oligonucleotide therapy: approaches to patient customization. Front Pharmacol 13:1006304","journal-title":"Front Pharmacol"},{"key":"5_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS, Norris D, Yu R et al (2015) Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87:46\u201351","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"5_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/hum.2015.070","volume":"26","author":"KE Lundin","year":"2015","unstructured":"Lundin KE, Gissberg O, Smith CI (2015) Oligonucleotide therapies: the past and the present. Hum Gene Ther 26(8):475\u2013485","journal-title":"Hum Gene Ther"},{"key":"5_CR6","first-page":"379","volume":"77","author":"M Butler","year":"1997","unstructured":"Butler M, Stecker K, Bennett CF (1997) Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest 77:379\u2013388","journal-title":"Lab Invest"},{"key":"5_CR7","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1080\/07328319708006272","volume":"16","author":"M Butler","year":"1997","unstructured":"Butler M, Stecker K, Bennett CF (1997) Histological localization of phosphorothioate oligodeoxynucleotides in normal rodent tissue. Nucleosides and Nucleotides 16:1761\u20131764","journal-title":"Nucleosides and Nucleotides"},{"key":"5_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0022-3565(24)35317-0","volume":"292","author":"M Butler","year":"2000","unstructured":"Butler M, Crooke RM, Graham MJ et al (2000) Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice. J Pharmacol Exp Ther 292:489\u2013496","journal-title":"J Pharmacol Exp Ther"},{"key":"5_CR9","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1093\/nar\/gkr089","volume":"39","author":"E Koller","year":"2011","unstructured":"Koller E, Vincent TM, Chappell A et al (2011) Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res 39:4795\u20134807","journal-title":"Nucleic Acids Res"},{"key":"5_CR10","doi-asserted-by":"publisher","first-page":"8796","DOI":"10.1093\/nar\/gku531","volume":"42","author":"TP Prakash","year":"2014","unstructured":"Prakash TP, Graham MJ, Yu J et al (2014) Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res 42:8796\u20138807","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"5_CR11","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1016\/j.drudis.2021.04.002","volume":"26","author":"L Weidolf","year":"2021","unstructured":"Weidolf L, Bj\u00f6rkbom A, Dahl\u00e9n A et al (2021) Distribution and biotransformation of therapeutic antisense oligonucleotides and conjugates. Drug Discov Today 26(10):2244\u20132258","journal-title":"Drug Discov Today"},{"issue":"6","key":"5_CR12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1089\/nat.2014.0506","volume":"24","author":"F Eckstein","year":"2014","unstructured":"Eckstein F (2014) Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther 24(6):374\u2013387","journal-title":"Nucleic Acid Ther"},{"issue":"4","key":"5_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1517\/17425250902877680","volume":"5","author":"RS Geary","year":"2009","unstructured":"Geary RS (2009) Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 5(4):381\u2013391","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"5_CR14","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz HB, Stanek LM, Wancewicz EV et al (2012) Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron 74:1031\u20131044","journal-title":"Neuron"},{"key":"5_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","volume":"28","author":"VA Korobeynikov","year":"2022","unstructured":"Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B et al (2022) Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med 28:104\u2013116","journal-title":"Nat Med"},{"key":"5_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.abm5527","volume":"14","author":"E Shao","year":"2022","unstructured":"Shao E, Chang CW, Li Z et al (2022) TAU ablation in excitatory neurons and postnatal TAU knockdown reduce epilepsy, SUDEP, and autism behaviours in a Dravet syndrome model. Sci Transl Med 14:1\u201316","journal-title":"Sci Transl Med"},{"issue":"4","key":"5_CR17","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.ymthe.2024.02.004","volume":"32","author":"MT Clarke","year":"2024","unstructured":"Clarke MT, Remesal L, Lentz L et al (2024) Prenatal delivery of a therapeutic antisense oligonucleotide achieves broad biodistribution in the brain and ameliorates Angelman syndrome phenotype in mice. Mol Ther 32(4):935\u2013951","journal-title":"Mol Ther"},{"issue":"1","key":"5_CR18","doi-asserted-by":"publisher","first-page":"102461","DOI":"10.1016\/j.omtn.2025.102461","volume":"36","author":"SJ Elliot","year":"2025","unstructured":"Elliot SJ, Anderson-Terhune D, Roos B et al (2025) Ratio of miRNA-29 to miRNA-199 expression coordinates mesenchymal stem cell repair of bleomycin-induced pulmonary injury. Mol Ther Nucleic Acids 36(1):102461","journal-title":"Mol Ther Nucleic Acids"},{"key":"5_CR19","volume-title":"RNA detection. Methods in molecular biology, vol 1649","author":"VP Yin","year":"2018","unstructured":"Yin VP (2018) In situ detection of microRNA expression with RNAscope probes. In: Gaspar I (Ed.)Eds. RNA detection. Methods in molecular biology, vol 1649. Humana Press, New York"},{"issue":"1","key":"5_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02061-x","volume":"23","author":"C Palazzo","year":"2025","unstructured":"Palazzo C, Mastrantonio R, Gioelli N et al (2025) Neuropilin 1-dependent paracrine signaling of cancer cells mediated by miRNA exosomal cargo. Cell Commun Signal 23(1):54","journal-title":"Cell Commun Signal"},{"issue":"6","key":"5_CR21","doi-asserted-by":"publisher","first-page":"70040","DOI":"10.1002\/lio2.70040","volume":"9","author":"AM Levin","year":"2024","unstructured":"Levin AM, Okifo O, Buhl K et al (2024) Higher expression of mir-31-5p is associated with reduced risk of head and neck keloid recurrence following surgical resection. Laryngoscope Investig Otolaryngol 9(6):70040","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"1","key":"5_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41420-023-01499-7","volume":"9","author":"J Gan","year":"2023","unstructured":"Gan J, Zhang Y, Liu S et al (2023) MicroRNA-375 restrains the progression of lung squamous cell carcinoma by modulating the ERK pathway via UBE3A-mediated DUSP1 degradation. Cell Death Discov 9(1):199","journal-title":"Cell Death Discov"},{"issue":"10","key":"5_CR23","first-page":"1575","volume":"29","author":"B Spencer-Dene","year":"2023","unstructured":"Spencer-Dene B, Mukherjee P, Alex A et al (2023) Localization of unlabeled bepirovirsen antisense oligonucleotide in murine tissues using in situ hybridization and CARS imaging. RNA 2023 29(10):1575\u20131590","journal-title":"RNA 2023"},{"key":"5_CR24","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41434-022-00316-7","volume":"29","author":"S Ait Benichou","year":"2022","unstructured":"Ait Benichou S, Jauvin D, De Serres-B\u00e9rard Tet al (2022) Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1. Gene Ther 29:698\u2013709","journal-title":"Gene Ther"},{"issue":"19","key":"5_CR25","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1016\/j.neuron.2024.07.013","volume":"112","author":"M Zhao","year":"2024","unstructured":"Zhao M, Cheng X, Chen L et al (2024) Antisense oligonucleotides enhance SLC20A2 expression and suppress brain calcification in a humanized mouse model. Neuron 112(19):3278\u20133294","journal-title":"Neuron"},{"issue":"11","key":"5_CR26","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1158\/1078-0432.CCR-23-3029","volume":"30","author":"J Brugarolas","year":"2024","unstructured":"Brugarolas J, Obara G, Beckermann KE et al (2024) A first-in-human phase 1 study of a tumor-directed RNA-interference drug against HIF2\u03b1 in patients with advanced clear cell renal cell carcinoma. Clin Cancer Res 30(11):2402\u20132411","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5_CR27","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1038\/s41467-023-40185-1","volume":"14","author":"C Beck","year":"2023","unstructured":"Beck C, Ramanujam D, Vaccarello P et al (2023) Trimannose-coupled antimiR-21 for macrophage-targeted inhalation treatment of acute inflammatory lung damage. Nat Commun 14(1):4564","journal-title":"Nat Commun"},{"issue":"1","key":"5_CR28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/01926233241311277","volume":"53","author":"V Dubost","year":"2025","unstructured":"Dubost V, Wuersch K, Penraat K et al (2025) Characterizing antisense oligonucleotide-induced histopathology findings in spinal cord of Mauritius Cynomolgus monkeys by molecular localization investigation. Toxicol Pathol 53(1):95\u2013106","journal-title":"Toxicol Pathol"},{"key":"5_CR29","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2144\/05384RR01","volume":"38","author":"L Hummelshoj","year":"2005","unstructured":"Hummelshoj L, Ryder LP, Madsen HO et al (2005) Locked nucleic acid inhibits amplification of contaminating DNA in real-time PCR. Biotechniques 38:605\u2013610","journal-title":"Biotechniques"},{"key":"5_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-4939-1459-3_7","volume":"1211","author":"BS Nielsen","year":"2014","unstructured":"Nielsen BS, M\u00f8ller T, Holmstr\u00f8m K (2014) Chromogen detection of microRNA in frozen clinical tissue samples using LNA\u2122 probe technology. Methods Mol Biol 1211:77\u201384","journal-title":"Methods Mol Biol"},{"issue":"4","key":"5_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0890-8508(03)00048-3","volume":"17","author":"AN Silahtaroglu","year":"2003","unstructured":"Silahtaroglu AN, Tommerup N, Vissing H et al (2003) FISHing with locked nucleic acids (LNA): evaluation of different LNA\/DNA mixmers. Mol Cell Probes 17(4):165\u2013169","journal-title":"Mol Cell Probes"},{"issue":"1","key":"5_CR32","doi-asserted-by":"publisher","first-page":"11043","DOI":"10.1038\/s41598-017-09147-8","volume":"7","author":"YV Pabon-Martinez","year":"2017","unstructured":"Pabon-Martinez YV, Xu Y, Villa A et al (2017) LNA effects on DNA binding and conformation: from single strand to duplex and triplex structures. Sci Rep 7(1):11043","journal-title":"Sci Rep"},{"issue":"2","key":"5_CR33","doi-asserted-by":"publisher","first-page":"102224","DOI":"10.1016\/j.omtn.2024.102224","volume":"35","author":"S Qassem","year":"2024","unstructured":"Qassem S, Breier D, Naidu GS et al (2024) Unlocking the therapeutic potential of locked nucleic acids through lipid nanoparticle delivery. Mol Ther Nucleic Acids 35(2):102224","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"5_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3109\/10520295.2013.839825","volume":"89","author":"U Singh","year":"2014","unstructured":"Singh U, Keirstead N, Wolujczyk A et al (2014) General principles and methods for routine automated microRNA in situ hybridization and double labeling with immunohistochemistry. Biotech Histochem 89(4):259\u2013266","journal-title":"Biotech Histochem"}],"container-title":["Methods in Molecular Biology","In Situ Hybridization Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5272-5_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:34:35Z","timestamp":1788302075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5272-5_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071652718","9781071652725"],"references-count":34,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5272-5_5","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"2 August 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this chapter.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}